check_circleStudy Completed

Multiple sclerosis

Bayer Identifier:

20750

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
RETAIN: Real world Evidence assessment of inTerferon beta-1b Adherence using autoINjectors

Trial purpose

Primary objective(s):
•   To describe medication possession ratio (MPR) and persistence rates over the 24-month period prior to (pre-BETACONNECT) and the 24-month period following the introduction and uptake of the BETACONNECT device (post-BETACONNECT) for patients with MS using Betaseron or Rebif.
Secondary objective(s):
•   To describe baseline demographic and clinical characteristics in the populations of interest.

Key Participants Requirements

Sex

All

Age

18 - N/A
  • Adult patients (≥ 18 years of age) who received at least one prescription for
    Betaseron or Rebif.

Trial summary

Enrollment Goal
1216
Trial Dates
October 2019 - February 2020
Phase
N/A
Could I Receive a placebo
N/A
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
United States

Trial design

Real world Evidence assessment of inTerferon beta-1b Adherence using autoINjectors
Trial Type
Observational
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A